242 related articles for article (PubMed ID: 19782085)
21. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study.
Castells L; Rimola A; Manzardo C; Valdivieso A; Montero JL; Barcena R; Abradelo M; Xiol X; Aguilera V; Salcedo M; Rodriguez M; Bernal C; Suarez F; Antela A; Olivares S; Del Campo S; Laguno M; Fernandez JR; de la Rosa G; Agüero F; Perez I; González-García J; Esteban-Mur JI; Miro JM;
J Hepatol; 2015 Jan; 62(1):92-100. PubMed ID: 25127748
[TBL] [Abstract][Full Text] [Related]
22. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
[TBL] [Abstract][Full Text] [Related]
23. [Efficacy and safety of peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C virus infection].
Delić D
Med Pregl; 2006; 59(9-10):415-9. PubMed ID: 17345816
[TBL] [Abstract][Full Text] [Related]
24. [Efficacy of combined antiviral therapy with pegylated interferon alpha-2a and ribavirin for chronic hepatitis C infection in intravenous drug users].
Ruzić M; Milotka F; Klasnja B; Pobor M; Svarc D; Jovelic A; Fabri I
Srp Arh Celok Lek; 2010; 138(1-2):43-9. PubMed ID: 20425908
[TBL] [Abstract][Full Text] [Related]
25. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection.
Flamm SL; Lawitz E; Jacobson I; Bourlière M; Hezode C; Vierling JM; Bacon BR; Niederau C; Sherman M; Goteti V; Sings HL; Barnard RO; Howe JA; Pedicone LD; Burroughs MH; Brass CA; Albrecht JK; Poordad F
Clin Gastroenterol Hepatol; 2013 Jan; 11(1):81-87.e4; quiz e5. PubMed ID: 23064222
[TBL] [Abstract][Full Text] [Related]
26. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents.
Sokal EM; Bourgois A; Stéphenne X; Silveira T; Porta G; Gardovska D; Fischler B; Kelly D
J Hepatol; 2010 Jun; 52(6):827-31. PubMed ID: 20400194
[TBL] [Abstract][Full Text] [Related]
27. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response.
Ferenci P; Laferl H; Scherzer TM; Gschwantler M; Maieron A; Brunner H; Stauber R; Bischof M; Bauer B; Datz C; Löschenberger K; Formann E; Staufer K; Steindl-Munda P;
Gastroenterology; 2008 Aug; 135(2):451-8. PubMed ID: 18503773
[TBL] [Abstract][Full Text] [Related]
28. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin.
Rossignol JF; Elfert A; El-Gohary Y; Keeffe EB
Gastroenterology; 2009 Mar; 136(3):856-62. PubMed ID: 19135998
[TBL] [Abstract][Full Text] [Related]
29. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
[TBL] [Abstract][Full Text] [Related]
30. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C.
Rumi MG; Aghemo A; Prati GM; D'Ambrosio R; Donato MF; Soffredini R; Del Ninno E; Russo A; Colombo M
Gastroenterology; 2010 Jan; 138(1):108-15. PubMed ID: 19766645
[TBL] [Abstract][Full Text] [Related]
31. Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b.
Foster GR
Drugs; 2010; 70(2):147-65. PubMed ID: 20108989
[TBL] [Abstract][Full Text] [Related]
32. Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b.
Scotto G; Fazio V; Fornabaio C; Tartaglia A; Di Tullio R; Saracino A; Angarano G
Drugs; 2008; 68(6):791-801. PubMed ID: 18416586
[TBL] [Abstract][Full Text] [Related]
33. Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4.
Al Ashgar H; Helmy A; Khan MQ; Al Kahtani K; Al Quaiz M; Rezeig M; Kagevi I; Alshehri A; Al Kalbani A; Al Swat K; Dahab S; Elkum N; Al Fadda M
Ann Saudi Med; 2009; 29(1):4-14. PubMed ID: 19139619
[TBL] [Abstract][Full Text] [Related]
34. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.
Shiffman ML; Di Bisceglie AM; Lindsay KL; Morishima C; Wright EC; Everson GT; Lok AS; Morgan TR; Bonkovsky HL; Lee WM; Dienstag JL; Ghany MG; Goodman ZD; Everhart JE;
Gastroenterology; 2004 Apr; 126(4):1015-23; discussion 947. PubMed ID: 15057741
[TBL] [Abstract][Full Text] [Related]
35. Meta-analysis shows extended therapy improves response of patients with chronic hepatitis C virus genotype 1 infection.
Farnik H; Lange CM; Sarrazin C; Kronenberger B; Zeuzem S; Herrmann E
Clin Gastroenterol Hepatol; 2010 Oct; 8(10):884-90. PubMed ID: 20601130
[TBL] [Abstract][Full Text] [Related]
36. Directly observed pegylated interferon plus self-administered ribavirin for the treatment of hepatitis C virus infection in people actively using drugs: a randomized controlled trial.
Hilsden RJ; Macphail G; Grebely J; Conway B; Lee SS
Clin Infect Dis; 2013 Aug; 57 Suppl 2():S90-6. PubMed ID: 23884072
[TBL] [Abstract][Full Text] [Related]
37. Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients.
Osinusi A; Bon D; Nelson A; Lee YJ; Poonia S; Shivakumar B; Cai SY; Wood B; Haagmans B; Lempicki R; Herrmann E; Sneller M; Polis M; Masur H; Kottilil S
J Med Virol; 2014 Feb; 86(2):177-85. PubMed ID: 24166150
[TBL] [Abstract][Full Text] [Related]
38. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin.
Swain MG; Lai MY; Shiffman ML; Cooksley WG; Zeuzem S; Dieterich DT; Abergel A; Pessôa MG; Lin A; Tietz A; Connell EV; Diago M
Gastroenterology; 2010 Nov; 139(5):1593-601. PubMed ID: 20637202
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study.
Tural C; Solà R; Rubio R; Santín M; Planas R; Quereda C; Berenguer J; Montes-Ramírez M; Clotet B;
J Viral Hepat; 2007 Oct; 14(10):704-13. PubMed ID: 17875005
[TBL] [Abstract][Full Text] [Related]
40. [Efficacy and safety of peginterferon alfa-2a and ribavirin treatment of chronic hepatitis C in the Republic of Serbia].
Božić M; Bojović K; Fabri M; Nožić D; Trkulja B; Milošević I
Srp Arh Celok Lek; 2012; 140(7-8):448-55. PubMed ID: 23092029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
